Show simple item record

dc.contributor.authorShah, Chirag B.
dc.contributor.authorMittelman, M. W.
dc.contributor.authorCosterton, J. William
dc.contributor.authorParenteau, Stephen
dc.contributor.authorPelak, Michael
dc.contributor.authorArsenault, Richard
dc.contributor.authorMermel, Leonard A.
dc.date.accessioned2017-08-17T17:22:04Z
dc.date.available2017-08-17T17:22:04Z
dc.date.issued2002-06
dc.identifier.citationShah, C.B., M.W. Mittelman, J.W. Costerton, S. Parenteau, M. Pelak, R. Arsenault, and L.A. Mermel, "Antimicrobial Activity of a Novel Catheter Lock Solution," Antimicrobial Agents and Chemotherapy Jun 2002en_US
dc.identifier.issn0066-4804
dc.identifier.urihttps://scholarworks.montana.edu/xmlui/handle/1/13541
dc.description.abstractIntravascular catheter-associated bloodstream infections significantly increase rates of morbidity and hospital costs. Microbial colonization and development of biofilms, which are known to be recalcitrant to antibiotic therapy, often lead to the loss of otherwise patent vascular access systems. We evaluated a new taurolidine- and citrate-based catheter lock solution (Neutrolin; Biolink Corporation, Norwell, Mass.) for its activity against planktonic microbes, antimicrobial activity in a catheter model, and biofilm eradication activity. In studies of planktonic microbes, after 24 h of contact, 675 mg of taurolidine-citrate solution per liter caused >99% reductions in the initial counts of Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, and Entercoccus faecalis. A solution of 13,500 mg/liter was cidal for Candida albicans. Ports and attached catheters inoculated with 50 to 600 CFU of these bloodstream isolates per ml were locked with heparin or the taurolidine-citrate solution. After 72 h, there was no growth in the taurolidine-citrate-treated devices but the heparin-treated devices exhibited growth in the range of 6 x 102 to 5 x 106 CFU/ml. Biofilms were developed on silicone disks in modified Robbins devices with broth containing 6% serum (initial counts, 106 to 108 CFU/cm2). The axenic biofilms were treated for 24 h with taurolidine-citrate or heparin. Taurolidine-citrate exposure resulted in a median reduction of 4.8 logs, whereas heparin treatment resulted in a median reduction of 1.7 logs (P < 0.01). No significant differences in the effects of the two treatments against P. aeruginosa and C. albicans were observed. These findings suggest that aurolidine-citrate is a promising combination agent for the prevention and treatment of intravascular catheter-related infections.en_US
dc.titleAntimicrobial activity of a novel catheter lock solutionen_US
dc.typeArticleen_US
mus.citation.extentfirstpage1674en_US
mus.citation.extentlastpage1679en_US
mus.citation.issue66en_US
mus.citation.journaltitleAntimicrobial Agents and Chemotherapyen_US
mus.citation.volume46en_US
mus.identifier.categoryEngineering & Computer Scienceen_US
mus.identifier.doi10.1128/aac.46.6.1674-1679.2002en_US
mus.relation.collegeCollege of Engineeringen_US
mus.relation.departmentCenter for Biofilm Engineering.en_US
mus.relation.departmentChemical & Biological Engineering.en_US
mus.relation.departmentChemical Engineering.en_US
mus.relation.universityMontana State University - Bozemanen_US
mus.relation.researchgroupCenter for Biofilm Engineering.en_US
mus.data.thumbpage2en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record